The market performance of Taysha Gene Therapies Inc’s stock has been harmonious in recent times. Over the last year, the company’s stock reached its highest point at $4.32 on 06/13/24, while the lowest value for the same duration was $1.19 on 11/05/24.
52-week price history of TSHA Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Taysha Gene Therapies Inc’s current trading price is -42.82% away from its 52-week high, while its distance from the 52-week low is 107.56%. The stock’s price range during the 52-week period has remained between $1.19 and $4.32. In the Healthcare sector, the company’s shares saw a trading volume of around 8.39 million for the day, which was evidently higher than the average daily volume of 3.23 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Taysha Gene Therapies Inc (TSHA) has experienced a quarterly rise of 14.35% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 573.55M and boasts a workforce of 52 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.09, with a change in price of +0.32. Similarly, Taysha Gene Therapies Inc recorded 2,678,616 in trading volume during the last 100 days, posting a change of +14.88%.
Examining TSHA’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for TSHA stands at 0.70. Similarly, the long-term debt-to-equity ratio is also 0.68.
TSHA Stock Stochastic Average
As of today, Taysha Gene Therapies Inc’s raw stochastic average for the last 50 days stands at 88.89%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 88.89%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 71.53% and 66.90%, respectively.
TSHA Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Until today this year the stock’s price performance recorded an increase of 39.55%. However, over the last six months, the performance has been stronger by -23.77%. The price of TSHA increased 25.38% over the last 30 days. And in the last five days, it has surged by 19.90%.
